Wallace Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Georgia Institute of Technology, Atlanta, GA, USA.
Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Transl Vis Sci Technol. 2024 Oct 1;13(10):14. doi: 10.1167/tvst.13.10.14.
Expansion of the suprachoroidal space (SCS) by a hydrogel injection has been shown to reduce intraocular pressure (IOP) in rabbits as a potential treatment for ocular hypertension in glaucoma. Here, we evaluate the safety and efficacy of this approach in hypertensive and normotensive eyes in nonhuman primates.
A microneedle was used to inject a hyaluronic acid-based hydrogel or saline solution (control) into the SCS of cynomolgus monkey eyes that were either normotensive (n = 7 experimental; n = 2 control eyes) or had induced ocular hypertension (n = 6 experimental; n = 3 control eyes). IOP and the degree of SCS expansion were monitored over time by tonometry and ultrasound biomicroscopy, respectively. Safety was evaluated through slit lamp, fundus, and histology examinations.
In hypertensive eyes, SCS injection with hydrogel initially reduced IOP by 47.5 ± 16.7%, and IOP returned to baseline in 38 days. In normotensive eyes, hydrogel injection initially reduced IOP by 38.8 ± 8.1% and IOP gradually returned to baseline also in 39 days. Sham injections resulted in mild IOP reduction in hypertensive eyes and normotensive eyes. The hydrogel injections were well tolerated by clinical assessments.
IOP was reduced in nonhuman primates for over one month by sustained SCS expansion. This procedure was safe and simple to perform. These data confirm the translational potential of this treatment method. Further optimization of the hydrogel may provide longer durations of IOP reduction.
A microneedle injection of hydrogel into the suprachoroidal space may provide a non-surgical, non-pharmacologic treatment for ocular hypertension in glaucoma patients.
通过向脉络膜上腔(SCS)注射水凝胶来扩张 SCS,已被证明可降低兔眼的眼压(IOP),作为治疗青光眼患者眼高压的潜在方法。在此,我们评估了这种方法在非人灵长类动物正常眼压眼和高血压眼中的安全性和有效性。
使用微针将透明质酸基水凝胶或生理盐水(对照)注射到正常眼压(实验:n = 7 只眼,对照:n = 2 只眼)或诱导性高血压(实验:n = 6 只眼,对照:n = 3 只眼)的食蟹猴眼中的 SCS 内。通过眼压计和超声生物显微镜分别监测眼压和 SCS 扩张程度随时间的变化。通过裂隙灯、眼底和组织学检查评估安全性。
在高血压眼中,水凝胶 SCS 注射最初使 IOP 降低 47.5±16.7%,38 天后 IOP 恢复基线。在正常眼压眼中,水凝胶注射最初使 IOP 降低 38.8±8.1%,39 天后 IOP 也逐渐恢复基线。假手术导致高血压眼和正常眼压眼的眼压轻度降低。临床评估显示水凝胶注射的耐受性良好。
通过持续的 SCS 扩张,非人类灵长类动物的 IOP 降低超过一个月。该程序安全且易于操作。这些数据证实了这种治疗方法的转化潜力。对水凝胶进一步优化可能会提供更长时间的 IOP 降低。
杨硕